Abstract:Background: Sorafenib is the first FDA approved first-line targeted drug for advanced HCC. However, resistance to sorafenib is frequently observed in clinical practice, and the molecular mechanism remains largely unknown. This study aimed to clarify the mechanism of sorafenib resistance and seek more effective treatments for HCC.Methods: Two sorafenib-resistant (SR) cell lines were established by continuous exposure to sorafenib. Global transcriptional consequences of sorafenib-resistant HCC was characterized, and immunoprecipitation-mass spectrometry (IP-MS) was performed to identify specific acetylation sites.Findings: PLEKHG5 was abundantly up-regulated in HCC patients and sorafenib-resistant cells, which was correlated with poor outcomes in HCC patients. PLEKHG5 overexpression activated the Rac1/AKT/NF-κB signaling and reduced sensitivity to sorafenib in HCC cells, while knockdown of PLEKHG5 increased sorafenib sensitivity. Histone deacetylase 2 (HDAC2) was directly interacted with PLEKHG5 to deacetylate its lysine sites within the PH domain and consequently maintain its stability. Moreover, HDAC2 inhibition (HDAC2 knockout or inhibitor) induced PLEKHG5 acetylation-related degradation and thereby enhanced the sensitivity of HCC to sorafenib in vitro and in vivo.Interpretation: Our work showed a novel mechanism for maintaining sorafenib resistance by HDAC2-mediated PLEKHG5 posttranslational modifications, and is a proof-of-concept study for targeting HDAC2 and PLEKHG5 in sorafenib-treated HCC patients as a new pharmaceutical intervention for advanced HCC.Funding Information: This work was supported by grants from the National Natural Science Foundation of China (no. 81602045; no. 81802454; no. U20A20392), the Basic and frontier research project of Yuzhong District, Chongqing (no. 20180118), and the Natural Science Foundation Project of Chongqing (no. cstc2016jcyjA0206). Declaration of Interests The authors declare that they have no competing interests.Ethics Approval Statement: The Institute Research Medical Ethics Committee of First Affiliated Hospital of Chongqing Medical University (Chongqing, China) granted approval for this study. At the time of tissue collection, informed consent was obtained from all patients.

S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Integrating Bulk-Rna and Single-Cell Analysis Reveals Heterogeneous Expression of Cuproptosis-Related Sorafenib-Resistant Genes in Hepatocellular Carcinoma

Activation of Phosphatidylinositol 3-Kinase/akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

Increasing AR by HIF-2α Inhibitor (PT-2385) Overcomes the Side-Effects of Sorafenib by Suppressing Hepatocellular Carcinoma Invasion Via Alteration of Pstat3, Pakt and Perk Signals

PLEKHG5, Stabilized by HDAC2-Related Deacetylation, Confers Sorafenib Resistance Through Regulating Rac1/AKT/NF-κB Signaling in HCC

Sorafenib with ASC-J9® Synergistically Suppresses the HCC Progression Via Altering the Pstat3-Ccl2/bcl2 Signals.

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma

PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma

Activation of Phosphatidylinositol 3-Kinase/akt Signaling Mediates Sorafenib-Induced Invasion and Metastasis in Hepatocellular Carcinoma

PLEKHG5 is Stabilized by HDAC2-related Deacetylation and Confers Sorafenib Resistance in Hepatocellular Carcinoma.

Pten Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib

Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy

Dipeptidyl peptidase‐8 induces sorafenib resistance via binding with c‐Rel to mediate NF‐κB signaling in hepatocellular carcinoma

Sestrin 2 Confers Primary Resistance to Sorafenib by Simultaneously Activating AKT and AMPK in Hepatocellular Carcinoma

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma

Activation Of Phosphatidylinositol 3-Kinase/Akt/Snail Signaling Pathway Contributes To Epithelial-Mesenchymal Transition-Induced Multi-Drug Resistance To Sorafenib In Hepatocellular Carcinoma Cells

PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells